Brief: Akoustis Technologies Q2 Basic EPS USD -0.21
13/02/2024 12:00
Feb 13 (Reuters) - Akoustis Technologies Q2 revenue USD 7.017 million vs. IBES estimate USD 6.99 million. * Q2 operating expenses USD 15.705 million * Q2 gross profit USD 681 thousand * Q2 operating income USD -15.024 million * Q2 net income USD -15.711 million * Q2 pretax profit USD -15.709 million
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut